Index
RUT
P/E
-
EPS (ttm)
-0.95
Insider Own
13.12%
Shs Outstand
438.11M
Perf Week
19.13%
Market Cap
1.84B
Forward P/E
-
EPS next Y
-0.31
Insider Trans
0.00%
Shs Float
387.94M
Perf Month
18.10%
Enterprise Value
1.57B
PEG
-
EPS next Q
-0.13
Inst Own
54.47%
Perf Quarter
42.21%
Income
-353.86M
P/S
6.43
EPS this Y
49.65%
Inst Trans
1.89%
Perf Half Y
81.86%
Sales
285.55M
P/B
2.49
EPS next Y
43.59%
ROA
-37.40%
Perf YTD
50.55%
Book/sh
1.65
P/C
5.85
EPS next 5Y
-
ROE
-47.51%
52W High
5.63 -27.00%
Perf Year
134.86%
Cash/sh
0.70
P/FCF
-
EPS past 3/5Y
23.93% 10.23%
ROIC
-46.22%
52W Low
1.66 147.59%
Perf 3Y
-48.56%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
25.04%
Volatility
7.87% 7.08%
Perf 5Y
-77.23%
Dividend TTM
-
EV/Sales
5.50
EPS Y/Y TTM
23.00%
Oper. Margin
-125.41%
ATR (14)
0.27
Perf 10Y
-24.73%
Dividend Ex-Date
-
Quick Ratio
3.15
Sales Y/Y TTM
34.26%
Profit Margin
-123.92%
RSI (14)
62.46
Dividend Gr. 3/5Y
- -
Current Ratio
3.60
EPS Q/Q
47.50%
SMA20
14.07%
Beta
0.69
Payout
-
Debt/Eq
0.07
Sales Q/Q
44.82%
SMA50
13.22%
Rel Volume
1.33
Prev Close
3.70
Employees
975
LT Debt/Eq
0.06
SMA200
45.66%
Avg Volume
17.25M
Price
4.11
IPO
Sep 01, 2009
Option/Short
Yes / Yes
Trades
Volume
22,944,259
Change
11.08%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-25-26 Upgrade Citizens
Mkt Perform → Mkt Outperform
$5
Jul-15-25 Downgrade Goldman
Neutral → Sell
$1
May-16-25 Downgrade UBS
Buy → Neutral
$2
May-12-25 Downgrade Truist
Buy → Hold
May-09-25 Downgrade Citizens JMP
Mkt Outperform → Mkt Perform
Oct-24-24 Initiated UBS
Buy
$17
Jul-29-24 Downgrade Piper Sandler
Overweight → Neutral
$19 → $10
Nov-20-23 Initiated Goldman
Buy
$12
Sep-18-23 Reiterated Barclays
Overweight
$40 → $18
May-30-23 Upgrade Wells Fargo
Equal Weight → Overweight
$11 → $17
Mar-27-23 Resumed Wells Fargo
Equal Weight
$11
Jan-27-23 Upgrade Piper Sandler
Neutral → Overweight
$11 → $14
Dec-09-22 Downgrade Goldman
Buy → Neutral
$20 → $6
Oct-31-22 Initiated Guggenheim
Neutral
Aug-18-22 Resumed Wells Fargo
Equal Weight
$14
Jan-28-22 Upgrade Stifel
Hold → Buy
$23 → $25
Dec-07-21 Resumed Cowen
Outperform
Jun-10-21 Upgrade JMP Securities
Mkt Perform → Mkt Outperform
$32
May-20-21 Downgrade Piper Sandler
Overweight → Neutral
$35 → $18
May-19-21 Downgrade Stifel
Buy → Hold
Show Previous Ratings
May-22-26 05:15PM
May-21-26 08:05AM
May-07-26 10:30AM
(Associated Press)
-13.20%
07:12AM
07:05AM
08:01AM
Loading…
Apr-27-26 08:01AM
Apr-17-26 05:15PM
Apr-15-26 05:13AM
Mar-31-26 08:49PM
Mar-24-26 10:00AM
Mar-20-26 05:15PM
Mar-07-26 08:10PM
01:28AM
Mar-06-26 01:06PM
12:01PM
09:00AM
Loading…
Mar-05-26 09:00AM
Feb-26-26 02:27PM
09:40AM
08:00AM
Feb-25-26 01:33PM
11:01AM
Feb-24-26 04:32PM
04:01PM
02:14PM
12:49PM
09:40AM
09:02AM
07:26AM
(Associated Press Finance)
07:00AM
07:00AM
09:58AM
Loading…
Feb-23-26 09:58AM
Feb-20-26 05:15PM
Feb-19-26 09:58AM
Feb-17-26 08:41PM
Feb-11-26 06:39PM
04:05PM
Feb-06-26 11:02AM
Feb-05-26 05:15PM
Jan-16-26 05:15PM
Jan-15-26 02:33PM
Dec-31-25 11:13AM
Dec-29-25 09:50AM
Dec-19-25 05:15PM
Dec-07-25 09:45AM
Nov-21-25 05:15PM
Nov-11-25 06:45AM
Nov-07-25 01:45PM
08:45AM
Nov-06-25 09:15AM
08:19AM
(Associated Press Finance)
08:00AM
Nov-05-25 05:20PM
Nov-04-25 06:00PM
Nov-03-25 10:00AM
07:00AM
Oct-23-25 04:05PM
Oct-17-25 05:15PM
06:17AM
Oct-15-25 08:45AM
Oct-13-25 05:53AM
Sep-20-25 02:43AM
Sep-19-25 05:00PM
10:05AM
Sep-17-25 08:30AM
Sep-08-25 12:30AM
Aug-29-25 08:30AM
Aug-27-25 04:28PM
Aug-26-25 09:17AM
Aug-25-25 05:15PM
10:30AM
(Associated Press Finance)
08:48AM
Aug-24-25 09:30AM
Aug-22-25 11:45PM
(Insider Monkey)
+5.91%
-5.95%
05:15PM
Aug-19-25 03:16PM
Aug-18-25 04:15PM
Aug-17-25 11:41PM
Aug-14-25 12:22PM
Aug-13-25 10:30AM
(Associated Press Finance)
+9.87%
Aug-12-25 05:31PM
Aug-09-25 04:21AM
Aug-08-25 07:31PM
(Motley Fool)
-20.08%
-6.64%
12:47PM
Aug-07-25 05:10PM
04:20PM
(Associated Press Finance)
04:01PM
06:02AM
Aug-06-25 06:10PM
Aug-05-25 06:05PM
Aug-01-25 06:46AM
Jul-30-25 04:46AM
Jul-29-25 03:29AM
Jul-24-25 04:05PM
10:30AM
(Associated Press Finance)
Jul-23-25 10:30AM
(Associated Press Finance)
+26.84%
Jul-21-25 08:30AM
Jul-18-25 05:15PM
Jul-15-25 07:30AM
Jul-14-25 07:30AM
Jul-10-25 04:01PM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
J.D. Dr. Frederick G. Vogt Esq.
Chief Financial Officer Ms. Corleen M. Roche
Chief Operating Officer Dr. Igor P. Bilinsky Ph.D.
Ph.D. Dr. Raj K. Puri M.D.
Chief Commercial Officer Mr. Daniel G. Kirby
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kirby Daniel Gordon Chief Commercial Officer May 11 '26 Option Exercise 0.00 10,000 0 149,381 May 13 05:00 PM Vogt Frederick G Interim CEO & General Counsel Mar 05 '26 Option Exercise 0.00 62,493 0 556,293 Mar 06 05:02 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Mar 05 '26 Option Exercise 0.00 31,246 0 148,477 Mar 06 05:01 PM Puri Raj K. Chief Regulatory Officer Mar 05 '26 Option Exercise 0.00 39,059 0 257,590 Mar 06 05:00 PM BILINSKY IGOR Chief Operating Officer Mar 05 '26 Option Exercise 0.00 31,246 0 142,394 Mar 06 05:00 PM Vogt Frederick G Interim CEO & General Counsel Mar 02 '26 Option Exercise 0.00 52,087 0 516,609 Mar 04 05:01 PM BILINSKY IGOR Chief Operating Officer Mar 02 '26 Option Exercise 0.00 12,307 0 118,051 Mar 04 05:01 PM Puri Raj K. Chief Regulatory Officer Mar 02 '26 Option Exercise 0.00 5,470 0 221,329 Mar 04 05:00 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Mar 02 '26 Option Exercise 0.00 12,697 0 124,353 Mar 04 05:00 PM Kirby Daniel Gordon Chief Commercial Officer Feb 24 '26 Option Exercise 0.00 120,000 0 173,546 Feb 26 05:00 PM Kirby Daniel Gordon Chief Commercial Officer Feb 10 '26 Option Exercise 0.00 39,996 0 69,996 Feb 12 05:00 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Dec 02 '25 Option Exercise 0.00 3,906 0 113,640 Dec 03 05:04 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Dec 01 '25 Option Exercise 0.00 8,789 0 114,198 Dec 03 05:04 PM BILINSKY IGOR Chief Operating Officer Dec 02 '25 Option Exercise 0.00 3,516 0 107,530 Dec 03 05:02 PM BILINSKY IGOR Chief Operating Officer Dec 01 '25 Option Exercise 0.00 8,789 0 108,478 Dec 03 05:02 PM Vogt Frederick G Interim CEO & General Counsel Dec 02 '25 Option Exercise 0.00 10,417 0 468,948 Dec 03 05:01 PM Vogt Frederick G Interim CEO & General Counsel Dec 01 '25 Option Exercise 0.00 41,669 0 476,232 Dec 03 05:01 PM Puri Raj K. Chief Regulatory Officer Dec 01 '25 Option Exercise 0.00 5,469 0 218,326 Dec 03 05:00 PM Vogt Frederick G Interim CEO & General Counsel Sep 02 '25 Option Exercise 0.00 52,086 0 456,690 Sep 04 06:35 PM Puri Raj K. Chief Regulatory Officer Sep 02 '25 Option Exercise 0.00 5,470 0 215,324 Sep 04 06:30 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Sep 02 '25 Option Exercise 0.00 12,697 0 111,857 Sep 04 06:30 PM BILINSKY IGOR Chief Operating Officer Sep 02 '25 Option Exercise 0.00 12,306 0 105,939 Sep 04 06:30 PM Kirby Daniel Gordon Chief Commercial Officer Jun 05 '25 Buy 1.84 30,000 55,200 30,000 Jun 06 04:05 PM Puri Raj K. Chief Regulatory Officer Jun 02 '25 Option Exercise 0.00 5,469 0 212,321 Jun 04 04:51 PM Vogt Frederick G Interim CEO & General Counsel Jun 02 '25 Option Exercise 0.00 52,085 0 426,731 Jun 04 04:50 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jun 02 '25 Option Exercise 0.00 12,695 0 105,608 Jun 04 04:49 PM BILINSKY IGOR Chief Operating Officer Jun 02 '25 Option Exercise 0.00 12,305 0 99,883 Jun 04 04:47 PM Bellemin Jean-Marc Chief Financial Officer Jun 02 '25 Option Exercise 0.00 8,789 0 64,993 Jun 04 04:46 PM
